Author: Marko Lukic (United Kingdom)
Co-authors: Laurence Cox, Yanda Li, Ian Yeung, Asha Ramanathan, Robin Hamilton, Ranjan Rajendram
Purpose
To assess patients' structural and functional outcomes of diabetic macular oedema non-responsive to anti-VEGF intravitreal injections treated with intravitreal fluocinolone acetonide (Iluvien).
Setting/Venue
This is a retrospective analysis of clinical data collected at Moorfields Eye Hospital, London, UK.
Methods
We identified 23 eyes non-responsive to intravitreal anti-VEGF injections treated for DMO who had intravitreal Iluvien implant between 2014 and 2019. Among the eyes included, we stratified those who had had and hadn't had intravitreal dexamethasone implant (Ozurdex) prior to the treatment with intravitreal Iluvien. We calculated visual acuity and anatomical outcomes for both subgroups and analysed the difference in overall results 12 months post-Iluvien implantation. The baseline for both subgroups was initiation with intravitreal anti-VEGF injections. Seventeen eyes met the criteria for this statistical analysis. We used ANOVA One-way analysis to calculate the p-value to compare the outcomes in each subgroup.
Results
The mean number of anti-VEGF injections received in all included patients was 8.2. Twelve eyes were switched from anti-VEGF to Iluiven implant (anti-VEGF/Iluvien subgroup) whilst 5 eyes were treated with Ozurdex prior to receiving an Iluiven implant (anti-VEGF/Ozurdex/Iluvien subgroup). The average number of Ozurdex implants was 1.75 [1-3]. In anti-VEGF/Iluvien subgroup, the mean VA (SD) at baseline was 52.27 ± 15.6 ETDRS letters whilst the mean VA (SD) 12 months post-Iluvien was 59.33 ± 15.2 ETDRS letters (p-value greater than 0.05). The CFT(SD) at baseline was 540 ± 197 µm whilst the mean CFT 12 months post-Iluvien was 368 ± 114 µm (p = .033). In anti-VEGF/Ozurdex/Iluvien subgroup, the mean VA (SD) at baseline was 45.2 ± 15.6 ETDRS letters whilst the mean VA(SD) 12 months post-Iluvien was 52.4 ± 16.7 ETDRS letters (p-value greater than 0.05). The CFT( SD) at baseline was 641 ± 161 µm whilst the mean CFT 12 months post-Iluvien was 329 ± 51 µm(p = .02).
Conlusions
Our real-life results may indicate that Ozurdex implant brings additional benefit in CFT reduction in patients with chronic, anti-VEGF non-responsive diabetic macular oedema prior treatment with long-lasting Iluvien implant, whilst there was no statistically significant improvement in visual acuity gain.
Financial Disclosure
Neither the speaker nor co-authors have any financial benefit from presenting this abstract. Other financial disclosure statements: Marko Lukic (presenter) received speaker fees and travel grants from Bayer and a speaker fee from Roche. Laurence Cox, Yanda Li, Asha Ramanathan, Ian Yeung, and Ranjan Rajendram have nothing to declare. Robin Hamilton has received grants, speaker fees, and was an advisory board member of Novartis, Bayer, Allergan, Ellex.
Comments
-